Human C-reactive protein (CRP) is an excellent clinical biomarker for the diagnosis, treatment and prognosis of inflammation and various related diseases such as viral infections and cardiovascular diseases. Herein, the expressed recombinant CRP as an antigen was used to immunize mice for establishing a rapid and accurate quantitative immunoassay for CRP. Five hybridoma cell lines for stable monoclonal antibody production were obtained. The developed monoclonal antibodies (mAbs) screened against human CRP were initially identified by a double antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA), and then mAb 9D6 and mAb 9G4 were selected as the capture and detection antibodies, respectively, to estab-lish the magnetic particle-based chemiluminescence enzyme immunoassay (CLEIA) for detection of CRP. Fi-nally, the analytical performance of the established CLEIA was evaluated by measuring CRP in clinical serum samples. The results showed that CLEIA based on the monoclonal antibody pair of 9D6/9G4-AP was charac-terized by the measurement interval from 0.176 7 μg/L to 500 μg/L (extended to 100 mg/L), and had an excel-lent correlation with the immune scattering turbidimetry commonly used in hospitals (R2: 0.949 6, P<0.000 1). In the Bland-Altman analysis, 96.36% (106/110) of the points were within the consistency limit of 95%, in-dicating that the two detection methods had good consistency. These results preliminarily showed that the developed analytical method may have a good application prospect in clinical diagnosis.